ReShape Lifesciences and Vyome Therapeutics merge, forming Vyome Holdings, Inc., focused on immuno-inflammatory assets with 11.1% ReShape stockholders ownership.
ReShape Lifesciences and Vyome Therapeutics have announced a merger agreement, creating a combined company focused on immuno-inflammatory asset development and U.S.-India market opportunities. ReShape stockholders will own 11.1% of the new company, named Vyome Holdings, Inc., which will trade under the Nasdaq ticker symbol "HIND." The merger is an all-stock transaction, with ReShape selling its medical devices to Biorad Medisys for $5.16 million in cash.
July 09, 2024
3 Articles